Review Article

Benefits of Equine-Assisted Therapies in People with Multiple Sclerosis: A Systematic Review

Table 1

Characteristics of the participants included in the systematic review.

StudyRandomizationGroupSample size (% of females)Age (SD)Years from diagnosis (SD)Disability level (SD)Body composition data (SD)

Moraes (2020) and Moraes (2021)Yes (RCT)EATGn = 17 (94.18%)45.5 (9.7)9 (6.1)EDSS (median): 2H: 162 (4.2)/W: 67 (13.1)/BCD: 25.5
ICGn = 16 (93.75%)44.8 (8.8)8.8 (5.7)EDSS (median): 1.75H: 163 (6.6)/W: 68.7 (13.4)/BCD: 25.9
Muñoz-Lasa (2019)No (non-RCT)EATGn = 6 (50%)41.3 (3.3)15.5 (5)NRNR
ICGn = 4 (25%)51.3 (4.6)17.5 (7.3)NRNR
Vermöhlen (2017)Yes (RCT)EATGn = 30 (90%)50 (median); R (45–53)16.5 (median) R (11–20)EDSS < 5 : 10 EDSS ≥ 5 : 20W: 67 (10.3)
CGn = 37 (72.97%)51 (median); R (47–56)17.6 (median) R (11–27)EDSS < 5 : 11 EDSS ≥ 5 : 26W: 70.6 (9.9)
Frevel (2015)Yes (RCT)EATGn = 9 (88.8%)46.9 (7.6)22.3 (8.3)EDSS: 3.8 (1.1)H: 167.9 (9.0)/W: 72.5 (12.3)/BCD: 25.7
ACGn = 9 (77.77%)44.3 (8.1)16.1 (11.3)EDSS: 3.8 (1.5)H: 168.2 (8.2)/W: 65.0 (8.9)/BCD: 23.03
Lindroth (2015)No (non-RCT)EATGN = 3 (66.66%)52.33 (13.28)14 (13.89)4 (1.32)NR
Menezes (2013)No (non-RCT)EATGn = 7 (85.71%)44 (9.1)8.6 (9.6)NRH: 162 (1)/W: 68.1 (16.6)/BCD: 25.9 (5.3)
ACGn = 4 (50%)40.3 (15.9)8.2 (5.6)NRH: 142 (6.2)/W: 72 (34.2)/BCD: 25.2 (25)
Muñoz-Lasa (2011)No (non-RCT)EATGn = 12 (58.33%)44.8. Range: 34–598.3 (7)EDSS: 5.2 (1.2)NR
ACGn = 15 (60%)46.2. Range: 38–647.8 (7)EDSS: 4.9 (1.3)NR
Silkwood-Sherer (2007)No (non-RCT)EATGn = 9 (55.55%)42.4 (14.2)9.9 (8.2)NRNR
ICGn = 6 (66.66%)47.7 (14.1)12.7 (6.6)NRNR
Hammer (2005)No (non-RCT)EATGn = 11 (81.8%)47.9 (8.4)10 (7)5 (6)NR

EATG: equine-assisted therapy group; ICG: control group; NR: not reported; SD: standard deviation; EDSS: Extended Disability Dtatus Scale; H: height (cm); W: weight (kg): BCD: body composition data; R: range; ACG: active control group.